Cancer Remission

Patients being followed for cancer account for 2.8% of emergency admissions in France. An acute episode that triggers a visit to the emergency department may be related to the progression of the disease, or to complications of treatment. The management of these patients is often complex and requires a degree of expertise. Emergency departments specialising in the management of cancer complications have been set up, and now deal exclusively with patients treated at their centres. However, for geographical or logistical reasons, patients with cancer are likely to consult a non-specialist emergency department and/or one located outside the cancer care centre. In this case, the emergency doctor may not have access to the oncology file, and care in the emergency department and downstream services may be sub-optimal. Studies have shown a positive impact on the quality of care and prognosis of patients thanks to the cancer centre's expertise. However, the effect of the centre on a cancer patient who visits the emergency department has never been studied. This is particularly true if the emergency department where the patient is seen is located in the cancer follow-up centre. The primary objective of the COVER study is to investigate the impact of the location of the emergency department where the patient is seen for their prognosis.

Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity. Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment. However, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission. This project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies. This work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU). Its objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care. This work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.

This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program.

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.